Formulation, Optimization and Evaluation of Rasagiline Mouth Dissolving Films

Abstract

The oral route is the most preferred route, though preoral administration of drug has disadvantage like hepatic first pass metabolism and enzymatic degradation within the GI tract. Trans-mucosal routes of drug delivery offer distinct advantage over preoral administration. The aim of present investigation was to formulate the fast-dissolving oral films (FDOF) of rasagiline, an anti-Parkinson drug. In the present study, rasagiline fast dissolving films were formulated by solvent-casting method containing HPMC 5cps, 15 cps and 50 cps as polymers and PEG 400 as plasticizer, Crospovidone and SSG as superdisintigrating agents. All films prepared were smooth and elegant in appearance and showed no visible cracks, were even in weight, thickness and drug content. Formulation F16 is considered as the optimized formulation as it showed the faster disintegration time i.e., 8±0.18 sec, good percentage elongation (9.4%), good folding endurance (120±4), and the in vitro drug release is 99.39±5.28% within 9 min. It can be concluded that from the study that the mouth dissolving film can be potential novel drug dosage for treatment of Parkinson’s disease.